Medicine & Life Sciences

1. Patient Reported Outcome Measures 100%
2. Lymphoma 51%
3. Terminology 45%
4. Lymphoma, Large B-Cell, Diffuse 37%
5. Clinical Trials 31%
6. Quality of Life 28%
7. Neoplasms 27%
8. Mantle-Cell Lymphoma 24%
9. Therapeutics 19%
10. Waldenstrom Macroglobulinemia 18%
11. Rituximab 17%
12. Positron-Emission Tomography 17%
13. Hematologic Neoplasms 15%
14. Recurrence 15%
15. Allogeneic Cells 14%
16. Survival 14%
17. Stem Cell Transplantation 12%
18. Survivorship 12%
19. National Cancer Institute (U.S.) 12%
20. Drug Therapy 11%
21. Incidence 10%
22. Fluorodeoxyglucose F18 10%
23. Chimeric Antigen Receptors 10%
24. Poecilia 10%
25. Fatigue 10%
26. Anthracyclines 10%
27. Cohort Studies 9%
28. Hodgkin Disease 9%
29. atezolizumab 9%
30. Prostatic Neoplasms 9%
31. Non-Hodgkin's Lymphoma 9%
32. Placebos 9%
33. Sinus Histiocytosis 9%
34. Progression-Free Survival 8%
35. Follicular Lymphoma 8%
36. Pragmatic Clinical Trials 8%
37. Prospective Studies 8%
38. B-Cell Lymphoma 8%
39. Transplants 8%
40. Peripheral T-Cell Lymphoma 8%
41. Nivolumab 8%
42. Essential Thrombocythemia 8%
43. Serotonergic Neurons 8%
44. Lenalidomide 8%
45. Adoptive Immunotherapy 8%
46. Methotrexate 7%
47. Dorsal Raphe Nucleus 7%
48. Nausea 7%